New Delhi [India], July 25: NovaLead Pharma Private Limited (NovaLead), the pioneer of drug repurposing in India announced today that the drug regulator in India, CDSCO has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need
Following a significant operation on December 12, last year, DRAP's team conducted a raid on an illicit pharmaceutical factory in Karachi, seizing a substantial quantity of counterfeit drugs.
The Drugs general controller (India) wrote a letter on December 18, to all states and asked states and Union Territories to update the package insert of products made using a cocktail of two medicines chlorpheniramine maleate and phenylephrine.
The FIA's anti-corruption unit detained Sheikh Akhtar Hussain, the ex-Chief Executive Officer of DRAP, following revelations that his appointment to the regulatory authority, based on a purported PhD degree, was discovered to be fake, according to an FIA spokesperson.
The regulatory alert issued by DRAP highlights that the deficiency in Sodium could lead to adverse reactions, causing pain in the body, weakness, throat swelling, and eye infections, according to ARY News.
Pakistan's largest city, Karachi, is currently facing a severe shortage of essential medicines, including life-saving drugs, which has worried patients and citizens in the city, as reported by ARY News.
During the operation in Lahore, significant measures were taken against those selling medicines above the approved prices, as reported by the spokesperson.
The alert comes as a result of potential health risks associated with the incorrect usage of the syrup, commonly employed in the treatment and prevention of iron deficiency anemia.
Union Health Minister Mansukh Mandaviya has directed the Drugs Controller General of India (DCGI) to take stringent actions against those pharmaceutical manufacturing companies that make spurious drugs.
After a Chennai-based pharmaceutical company was flagged by US authorities for lethal contamination in the eye drops, members of Tamil Nadu's Drug Controller and Central Drug Control Authority conducted a late-night inspection of Global Pharma Healthcare Private Limited, sources said.
After the US regulator Food and Drug Administration warned consumers "not to purchase or use EzriCare Artificial Tears due to potential contamination", the Central Drugs Standard Control Organization (CDSCO) under the Union Health ministry and the Tamil Nadu State Drug Controller have ini
The product will be manufactured at Granules manufacturing facility in Chantilly, Virginia, and is expected to be launched shortly, according to a company statement shared with stock exchanges.